RxDoctor Payments Data

Digant Bhatt, MD

Cardiovascular Disease · Cartersville, GANPI 1902045495

Payments from drug & device makers

$8,975in general payments, 2019–2025

Across 181 payments — averaging $49.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$6K
  • Novartis$662
  • Pfizer$408
  • Johnson & Johnson$322
  • Actelion Pharmaceuticals US, Inc.$214
  • Cvrx, Inc.$163
  • plus $1K from 20 others

What the payments were for

  • Speaking & faculty fees$5,25058%
  • Food & beverage$3,61540%
  • Education$1091%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,975 in reported general payments places this provider in the 80th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$376,432
Medicare patients
1,039
Services billed
9,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban437$435,505
XareltoRivaroxaban171$170,440
EntrestoSacubitril/Valsartan91$87,870
JardianceEmpagliflozin42$52,064
FarxigaDapagliflozin Propanediol54$47,061
Repatha SureclickEvolocumab52$35,515
BrilintaTicagrelor28$21,502
Ranolazine ErRanolazine103$12,185
CorlanorIvabradine Hcl13$8,462
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,168
Diltiazem 24hr Er (Cd)Diltiazem Hcl128$3,036
Potassium Chloride106$2,952
Atorvastatin Calcium484$2,849
Torsemide100$2,614
Metoprolol Succinate244$2,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$408$435,505437 claims
Johnson & JohnsonXarelto$322$170,440171 claims
NovartisEntresto$662$87,87091 claims
AstraZenecaFarxiga, Brilinta$144$68,56382 claims
Boehringer IngelheimJardiance$63$52,06442 claims
AmgenCorlanor$88$8,46213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Cartersville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →